Compare Charles River Laboratories Intl. Inc (CRL) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Global X NASDAQ 100 Covered Call ETF trades at $18.69 (market cap $8.49B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Global X NASDAQ 100 Covered Call ETF is more actively traded (2,913,938 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Global X NASDAQ 100 Covered Call ETF for 51 Days on average.
| CRL | QYLD | |
|---|---|---|
Market Cap | $14.23B | $8.49B |
Volume | 1,176,885 | 2,913,938 |
Sector | Health | Income / Options Overlay |
52-Week High | $310.77 | $18.68 |
52-Week Low | $149.93 | $16.70 |
Typical Hold Time | 33 Days | 51 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
QYLD trades at $18.66, showing minimal daily movement with a slight decline of -0.11%. The ETF maintains a consistent monthly dividend distribution of $0.18 per share, with technical indicators showing mixed signals—bullish moving averages but bearish oscillators including overbought RSI readings. Recent news highlights QYLD's high yield strategy but raises concerns about long-term capital erosion and tax implications.
QYLD offers high monthly income through covered call strategies but faces significant risks from capped upside potential and principal erosion. The ETF's distribution sustainability depends on Nasdaq volatility, with recent articles warning about declining option premiums. Investors should weigh the trade-off between immediate income and long-term capital preservation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
